• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Zimmer Biomet shares rise on Q4, 2018 earnings beat

Zimmer Biomet shares rise on Q4, 2018 earnings beat

February 1, 2019 By Fink Densford

Zimmer Biomet logo

Shares in Zimmer Biomet (NYSE:ZBH) rose today after the medical device maker beat expectations on Wall Street with its fourth quarter and full year 2018 earnings results.

The Warsaw, Ind.-based company posted losses of $902.5 million, or $4.42 per share, on sales of approximately $2.07 billion for the three months ended December 31, seeing a swing into the red while sales grew 0.1% compared with the same period during the previous year.

Adjusted to exclude one-time items, earnings per share were $2.18, a single cent ahead of the $2.17 consensus on Wall Street, where analysts expected to see sales of $2.06 billion, which the company also topped.

For the full year, Zimmer Biomet posted a loss of $379.2 million, or a loss of $1.86 per share, on sales of approximately $7.93 billion. Sales grew 1.7% compared with the previous year.

After adjusting to exclude one-time items, earnings per share were $7.64, again a single cent ahead of the consensus on Wall Street where analysts expected to see sales of $7.92 billion, which the company topped.

“We are encouraged with the solid close to 2018, driven by strong fourth quarter performance in the Asia Pacific and Europe, Middle East and Africa regions, and in our spine & CMF category. Overall, our financial results for the full year were in-line with our expectations for the progress of the turnaround of the business, and increase our confidence in achieving our 2019 objectives.  We look forward to delivering on our near-term commitments to transition to offense and drive enhanced shareholder value, including the launch of a number of exciting new products and platform technologies to expand our ecosystem of differentiated solutions,” prez & CEO Bryan Hanson said in a prepared statement.

The company provided guidance for 2019, expecting to see sales growth of between -0.5% and 0.5%. Zimmer Biomet said that it expects to post adjusted diluted EPS of between $7.70 and $7.90 for the year, with an adjusted operating profit margin of between 27% and 28%.

Shares in Zimmer Biomet have risen approximately 6.6% today, at $116.83 as of 9:56 a.m. EST.

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Zimmer Biomet

More recent news

  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes
  • FDA posts alert for Edwards Lifesciences mitral valve delivery system after patient death
  • Former Medtronic RDN leader joins Teleflex
  • CMR Surgical CEO outlines the path forward for Stryker’s robotics partnership
  • Stryker earns FDA clearance for new bone and soft tissue removal platform

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy